GLP1-imaging Before and After Bariatric Surgery

NCT03182231 · Unknown status

Last updated 2026-05-28

This clinical trial is testing how a special imaging scan (68Ga-NODAGA-exendin-4) detects changes in the pancreas of adults with type 2 diabetes who are planning to undergo weight-loss surgery.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase1, Phase2

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 12 people Planned (estimated).

Who can join Ages 18+ · female only

Timeline Started 2016-10 · est. completion 2023-07

Where 2 sites · Netherlands

What this study is testing ClinicalTrials.gov NCT03182231 ↗

Description as written by the study sponsor.

In order to evaluate the difference in beta cell mass in morbidly obese patients with type 2 diabetes mellitus (T2D) before and after Roux-en-Y gastric bypass (RYGB), investigators aim to compare quantitative PET imaging of the pancreas in this patient group before and after surgery. Investigators propose to measure the uptake of 68Ga-NODAGA-exendin-4 in the pancreatic beta cells of these patients. Furthermore, investigators aim to compare uptake of the radiolabeled tracer to beta cell function measured by laboratory parameters. These highly relevant data will provide investigators with more information on the contribution of the beta cells to the mechanisms behind resolution of T2D after bariatric surgery and on the prognostic value of pre-operative beta cell mass determination to T2D resolution. This might be of great interest for the assessment of RYGB as an alternative therapy in patients with T2D and a BMI \<35, who currently do not meet the international guidelines for bariatric surgery.

Treatments tested

68Ga-NODAGA-exendin-4 PET/CT Radiation

68Ga-NODAGA-exendin-4 PET/CT

Main thing measured	Pancreatic uptake of 68Ga-NODAGA-exendin-4
Sponsor	Radboud University Medical Center
Conditions studied	Diabetes Mellitus, Type 2, Bariatric Surgery Candidate
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03182231 ↗